We're unable to sign you in at this time. Please try again in a few minutes.
We were able to sign you in, but your subscription(s) could not be found. Please try again in a few minutes.
There may be a problem with your account. Please contact the AMA Service Center to resolve this issue.
Contact the AMA Service Center:
Telephone: 1 (800) 262-2350 or 1 (312) 670-7827  *   Email: subscriptions@jamanetwork.com
Error Message ......
Grand Rounds |

Advances in Molecular Genetics and Management of Hypertrophic Cardiomyopathy

Lameh Fananapazir, MD, FRCP
JAMA. 1999;281(18):1746-1752. doi:10.1001/jama.281.18.1746.
Text Size: A A A
Published online


Fananapazir L, Epstein ND.Prevalence of hypertrophic cardiomyopathy and limitations of screening methods. Circulation.1995;92:700-704.
Wigle ED, Rakowski H, Kimball BP, Williams WG.Hypertrophic cardiomyopathy: clinical spectrum and treatment. Circulation.1995;92:1680-1692.
Fananapazir L, McAreavey D, Epstein ND.Hypertrophic cardiomyopathy.In: Zipes D, Jalife J, eds. Cardiac Electrophysiology, From Cell to BedsidePhiladelphia: WB Saunders Co; 1995:769-779.
Fananapazir L, McAreavey D.Hypertrophic cardiomyopathy: evaluation and treatment of patients at high risk for sudden death. Pacing Clin Electrophysiol.1997;20:478-501.
Geisterfer-Lowrance AAT, Kass S, Tanigawa G.  et al. A molecular basis for familial hypertrophic cardiomyopathy: a beta cardiac myosin heavy chain gene missense mutation. Cell.1990;62:999-1006.
Thierfelder L, Watkins H, MacRae C.  et al. Alpha-tropomyosin and cardiac troponin T mutations cause familial hypertrophic cardiomyopathy: a disease of the sarcomere. Cell.1994;77:701-712.
Bonne G, Carrier L, Bercovici J.  et al. Cardiac myosin binding protein-C splice receptor mutation is associated with familial hypertrophic cardiomyopathy. Nat Genet.1995;11:438-440.
Poetter K, Jiang He, Hassanzadeh S.  et al. Mutations in either the essential or regulatory light chains of myosin are associated with a rare myopathy in human heart and skeletal muscle. Nat Genet.1996;13:63-69.
Kimura A, Harada H, Park JE.  et al. Mutations in the cardiac troponin I gene associated with hypertrophic cardiomyopathy. Nat Genet.1997;16:379-382.
MacRae CA, Ghaisas N, Kass S.  et al. Familial hypertrophic cardiomyopathy with Wolff-Parkinson-White syndrome maps to a locus on chromosome 7q3. J Clin Invest.1995;96:1216-1220.
Bonne G, Carrier L, Richard P, Hainque B, Schwartz K.Familial hypertrophic cardiomyopathy: from mutations to functional defects. Circ Res.1998;83:580-593.
Epstein ND, Cohn GM, Cyran F, Fananapazir L.Differences in clinical expression of hypertrophic cardiomyopathy associated with two distinct mutations in the β-myosin heavy chain gene: a 908Leu-Val mutation and a 403Arg-Gln mutation. Circulation.1992;86:345-352.
Fananapazir L, Epstein ND.Genotype-phenotype correlations in hypertrophic cardiomyopathy: insights provided by comparisons of kindreds with distinct and identical β-myosin heavy chain gene mutations. Circulation.1994;89:22-32.
Rayment I, Holden HM, Sellers J, Fananapazir L, Epstein ND.Structural interpretation of the mutations in the β-cardiac myosin that have been implicated in familial hypertrophic cardiomyopathy. Proc Natl Acad Sci U S A.1995;92:3864-3868.
Cuda G, Fananapazir L, Zhu WS, Sellers JR, Epstein ND.Skeletal muscle expression and abnormal function of β-myosin in hypertrophic cardiomyopathy. J Clin Invest.1993;91:2861-2865.
Lankford EB, Sweeney HL, Epstein ND, Fananapazir L.Abnormal contractile properties of muscle fibers expressing mutations in β-myosin in patients with hypertrophic cardiomyopathy. J Clin Invest.1995;95:1409-1414.
Cuda G, Fananapazir L, Epstein ND, Sellers JR.The in vitro motility activity of β-cardiac myosin depends on the nature of the β-myosin heavy-chain gene mutation in hypertrophic cardiomyopathy. J Muscle Res Cell Motil.1997;18:1-9.
Fananapazir L, Dalakas MC, Cyran F, Cohn G, Epstein ND.Missense mutations in the β-myosin heavy-chain gene cause central core disease in hypertrophic cardiomyopathy. Proc Natl Acad Sci U S A.1993:90:3993-3997.
Kramer CM, Reichek N, Ferrari VA, Theobald T, Dawson J, Axel L.Regional heterogeneity of function in hypertrophic cardiomyopathy. Circulation.1994;90:186-194.
Rigat B, Hubert C, Allenc-Gellas F, Cambien F, Corvol P, Soubrier F.An insertion/deletion polymorphism in the angiotensin I-converting enzyme gene accounting for half the variance of serum enzyme levels. J Clin Invest.1990;86:1343-1346.
Lechin M, Yu QT, Workman R, Greve G, Roberts R.Angiotensin-converting enzyme polymorphism in hypertrophic cardiomyopathy [abstract]. Circulation.1994;90(suppl I):I-174.
Fananapazir L, Masters S, Winkler J.  et al. ACE gene polymorphism and ACE levels as determinants of left ventricular hypertrophy in hypertrophic cardiomyopathy caused by β-myosin heavy-chain mutations [abstract]. Circulation.1996;94:I-110.
Molkentin JD, Lu J, Antos C.  et al. A calcineurin-dependent transcriptional pathway for cardiac hypertrophy. Cell.1998;93:215-228.
Palmiter KA, Solaro RJ.Molecular mechanisms regulating the myofilament response to Ca2+: implications of mutations causal for familial hypertrophic cardiomyopathy. Basic Res Cardiol.1997;92:63-74.
Sussman MA, Lim HW, Gude N.  et al. Prevention of cardiac hypertrophy in mice by calcineurin inhibition. Science.1998;281:1690-1693.
Fananapazir L, Chang AC, Epstein SE, McAreavey D.Prognostic determinants in hypertrophic cardiomyopathy: prospective evaluation of a therapeutic strategy based on clinical, Holter, hemodynamic, and electrophysiologic findings. Circulation.1992;86:730-740.
Fananapazir L, Leon MB, Cannon RO, Bonow RO, Winkler J, Epstein SE.Sudden death during empiric amiodarone therapy in symptomatic patients with hypertrophic cardiomyopathy. Am J Cardiol.1991;67:169-174.
O'Donoghue S, Platia E, Mispireta L.  et al. Safety of defibrillator implantation in patients with hypertrophic cardiomyopathy [abstract]. J Am Coll Cardiol.1994;23:11.
Zhu DW, Sun H, Hill R, Roberts R.The value of electrophysiology study and prophylactic implantation of cardioverter defibrillator in patients with hypertrophic cardiomyopathy. Pacing Clin Electrophysiol.1998;21(1 pt 2):299-302.
Dilsizian V, Bonow RO, Epstein SE, Fananapazir L.Myocardial ischemia detected by Thallium scintigraphy is frequently related to cardiac arrest and syncope in young patients with hypertrophic cardiomyopathy. J Am Coll Cardiol.1993;22:796-804.
Fananapazir L, McAreavey D.Therapeutic options in patients with obstructive HCM and severe drug-refractory symptoms. J Am Coll Cardiol.1998;31:259-264.
Fananapazir L, Atiga W, Tripodi D, Steele S, McAreavey D.Obstructive hypertrophic cardiomyopathy: therapeutic options.In: Barold SS, Mugica J, eds. Advances in Cardiac Pacing: Goals for the 21st CenturyVol 4. Armonk, NY: Futurea Publishing Co; 1998:35-48.
Sigwart U.Non-surgical myocardial reduction for hypertrophic obstructive cardiomyopathy. Lancet.1995;346:211-214.
Geitzen F, Leuner C, Gerenkamp T, Kuhn H.Transcoronary ablation of septal hypertrophy: a new catheter interventional therapy of hypertrophic obstructive cardiomyopathy. Circulation.1996;94(suppl 1):I84.
Seggewiss H, Gleichmann U, Faber L.  et al. Percutaneous transluminal myocardial ablation (PTSMA) in hypertrophic obstructive cardiomyopathy: acute results and 3-month follow-up in 25 patients. J Am Coll Cardiol.1998;31:252-258.
Lakkis NM, Nagueh SF, Kleiman NS.  et al. Echocardiographic-guided ethanol septal reduction for hypertrophic obstructive cardiomyopathy. Circulation.1998;98:1750-1755.
Faber L, Seggewiss H, Gleichmann U.Percutaneous transluminal septal myocardial ablation in hypertrophic obstructive cardiomyopathy. Circulation.1998;98:2515-2421.
Figures in this Article

Sign in

Purchase Options

• Buy this article
• Subscribe to the journal
• Rent this article ?

First Page Preview

View Large
First page PDF preview


Figure 1. Rare Left Ventricular Morphology in Hypertrophic Cardiomyopathy Caused by Specific Genetic Defects
Graphic Jump Location
A, Left ventricular (LV) angiograph in a patient with midcavity obstructive hypertrophic cardiomyopathy (HCM) caused by Met149Val mutation of the essential light chain of myosin. B, Left ventricular angiogram in patient with midcavity obstructive HCM caused by Glu22Lys mutation of the regulatory light chain of myosin. In both cases, massive LV hypertrophy at the level of the papillary muscles has reduced LV chamber size to a narrow tunnel that connects the proximal LV cavity to a distal aneurysm. Atrial and ventricular pacing leads are also evident. C, Left ventricular angiogram in an HCM patient with Leu908Val β-myosin mutation. The midcavity hypertrophy has caused subtotal obstruction, preventing contrast from filling of a distal aneurysm.
Figure 2. Sarcomere Contractile Proteins
Graphic Jump Location
The sarcomere is made up of contractile proteins organized into thick and thin filaments. The thick filament consists of β-myosin heavy chains (Myosin), essential light chains (ELC), and regulatory light chains (RLC). The thin filament consists of several proteins including actin, tropomyosin (α Tm), troponin C (TnC), troponin I (TnI), and troponin T (TTnT). Myosin has 3 functional domains: a head, a neck, and a tail (or rod). The myosin head contains an adenosine triphosphate–binding pocket (ATP cleft), and an actin binding site. The neck allows extension of the myosin for interaction with actin, and the tail anchors the molecule. Hydrolysis of ATP to adenosin diphosphate and Pi by (ATPase activity of the myosin head) powers translocation of actin by the myosin head. Binding of an ATP to myosin then dissociates myosin from actin. In hypertrophic cardiomyopathy, sarcomeric mutations may affect different stages of this contraction and relaxation process and interfere with the proper functioning of the myosin molecular motor.



Also Meets CME requirements for:
Browse CME for all U.S. States
Accreditation Information
The American Medical Association is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians. The AMA designates this journal-based CME activity for a maximum of 1 AMA PRA Category 1 CreditTM per course. Physicians should claim only the credit commensurate with the extent of their participation in the activity. Physicians who complete the CME course and score at least 80% correct on the quiz are eligible for AMA PRA Category 1 CreditTM.
Note: You must get at least of the answers correct to pass this quiz.
Please click the checkbox indicating that you have read the full article in order to submit your answers.
Your answers have been saved for later.
You have not filled in all the answers to complete this quiz
The following questions were not answered:
Sorry, you have unsuccessfully completed this CME quiz with a score of
The following questions were not answered correctly:
Commitment to Change (optional):
Indicate what change(s) you will implement in your practice, if any, based on this CME course.
Your quiz results:
The filled radio buttons indicate your responses. The preferred responses are highlighted
For CME Course: A Proposed Model for Initial Assessment and Management of Acute Heart Failure Syndromes
Indicate what changes(s) you will implement in your practice, if any, based on this CME course.


Some tools below are only available to our subscribers or users with an online account.

29 Citations

Sign in

Purchase Options

• Buy this article
• Subscribe to the journal
• Rent this article ?

Related Content

Customize your page view by dragging & repositioning the boxes below.

Articles Related By Topic
Related Collections
PubMed Articles

The Rational Clinical Examination: Evidence-Based Clinical Diagnosis
Original Article: Does This Patient Have an Abnormal Systolic Murmur?

The Rational Clinical Examination: Evidence-Based Clinical Diagnosis
Is This an Abnormal Murmur?